Endogenous and exogenous cardiac glycosides: Their roles in hypertension, salt metabolism, and cell growth

American Journal of Physiology - Cell Physiology

Volumn 293, Issue 2, 2007, Pages

  Schoner, Wilhelm ^a   Scheiner Bobis, Georgios ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Arterial hypertension; Bufalin; Cancer therapy; Cell proliferation; Endogenous cardiotonic steroids; Marinobufagenin; Oleandrin; Ouabain; Rostafuroxin; Sodium metabolism; Sodium pump; Sodium potassium adenosinetriphosphatase

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTIHYPERTENSIVE AGENT; BUFADIENOLIDE DERIVATIVE; BUFALIN; CALCIUM; CARDENOLIDE DERIVATIVE; CARDIAC GLYCOSIDE; DIGOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MARINOBUFAGENIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OLEANDRIN; OUABAIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; ROSTAFUROXIN; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL; SODIUM CHLORIDE; UNBS 1450; UNCLASSIFIED DRUG;

BRAIN METASTASIS; CANCER GROWTH; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; DRUG MECHANISM; HEART CONTRACTION; HUMAN; HYPERTENSION; LIVER METASTASIS; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SODIUM CALCIUM EXCHANGE; TUMOR CELL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; BLOOD PRESSURE; BUFANOLIDES; CALCIUM; CARDIAC GLYCOSIDES; CARDIOVASCULAR SYSTEM; CELL DEATH; CELL PROLIFERATION; DIABETES MELLITUS; DIGOXIN; HUMANS; HYPERTENSION; MOLECULAR STRUCTURE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; NA(+)-K(+)-EXCHANGING ATPASE; NEOPLASMS; OUABAIN; SODIUM CHLORIDE; STRUCTURE-ACTIVITY RELATIONSHIP;

MAMMALIA; STROPHANTHUS GRATUS;

EID: 34547733409     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00098.2007     Document Type: Review

References (418)

1. Abramowitz J, Dai C, Hirschi KK, Dmitrieva RI, Doris PA, Liu L, Allen JC. Ouabain- and marinobufagenin-induced proliferation of human umbilical vein smooth muscle cells and rat vascular smooth muscle cell line, A7r5. Circulation 108: 3048-3053, 2003.
2. Abreu GR, Futuro Neto HA, Cabral AM, Vasquez EC. Ouabain produces diverse excitatory effects on afferent baroreceptor nerve activity in SHR and WKY animals. Clin Exp Hypertens 20: 85-94, 1998.
3. Adair CD, Buckalew V, Taylor K, Ernest JM, Frye AH, Veille JC. Elevated endoxin-like factor complicating a multifetal second trimester pregnancy: treatment with digoxin-binding immunoglobulin. Am J Nephrol 16: 529-531, 1996.
4. Ahmed A, Pitt B, Rahimtoola SH, Waagstein F, White M, Love TE, Braunwald E. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol. In press. doi: 10.1016/j.ijcard.2006.12.001.
5. Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS, Adams KF, Gheorghiade M. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27: 178-186, 2006.
6. Aileru AA, De Albuquerque A, Hamlyn JM, Manunta P, Shah JR, Hamilton MJ, Weinreich D. Synaptic plasticity in sympathetic ganglia from acquired and inherited forms of ouabain-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 281: R635-R644, 2001.
7. Aizman O, Uhlén P, Lal M, Brismar H, Aperia A. Ouabain, a steroid hormone that signals with slow calcium oscillations. Proc Natl Acad Sci USA 98: 13420-13424, 2001.
8. o sensor: role in cardiovascular disease pathogenesis and augmented production of endogenous cardiotonic steroids. Pathophysiology 13: 209-216, 2006.
9. Akiyama M, Ogura M, Iwai M, Iijima M, Numazawa S, Yoshida T. Effect of bufalin on growth and differentiation of human skin carcinoma cells in vitro. Hum Cell 12: 205-209, 1999.
10. Al-Khalili L, Kotova O, Tsuchida H, Ehrén I, Féraille E, Krook A, Chibalin AV. ERK1/2 mediates insulin stimulation of Na,K-ATPase by phosphorylation of the α-subunit in human skeletal muscle cells. J Biol Chem 279: 25211-25218, 2004.
11. 2+ exchanger function. J Physiol 575: 845-454, 2006.
12. +-ATPase. Am J Physiol Renal Fluid Electrolyte Physiol 258: F144-F153, 1990.
13. Antonipillai I, Schick K, Horton R. Ouabain is a potent inhibitor of aldosterone secretion and angiotensin action in the human adrenal. J Clin Endocrinol Metab 81: 2335-2337, 1996.
14. 2+ signaling in arterial myocytes. Am J Physiol Cell Physiol 278: C163-C173, 2000.
15. 2+ transients in arterial smooth muscle without raising cytosolic Na. Am J Physiol Heart Circ Physiol 279: H679-H691, 2000.
16. Aronow WS. Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure. Cardiol Rev 14: 108-124, 2006.
17. Aydemir-Koksoy A, Abramowitz J, Allen J. Ouabain-induced signaling and vascular smooth muscle cell proliferation. J Biol Chem 276: 46605-46611, 2001.
18. +-ATPase inhibitor in patients after acute myocardial infarction. Hypertension 31: 1097-1103, 1998.
19. Bagrov AY, Fedorova OV, Maslova MN, Roukoyatkina NI, Ukhanova MA, Zhabko EP. Endogenous plasma Na,K-ATPase inhibitory activity and digoxin-like immunoreactivity after acute myocardial infarction. Cardiovasc Res 25: 371-377, 1991.
20. + ATPase inhibition during voluntary hypoventilation. Hypertension 26: 781-188, 1995.
21. Bagrov AY, Feodorova OV, Dmitrieva RI, French AW, Anderson DE. Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anaesthetized dogs. Cardiovasc Res 31: 296-305, 1996.
22. Bagrov YY, Manusova NB, Egorova IA, Fedorova OV, Bagrov AY. Endogenous digitalis-like ligands and Na/K-ATPase inhibition in experimental diabetes mellitus. Front Biosci 10: 2257-2262, 2005.
23. Balzan S, D'Urso G, Nicolini G, Forini F, Montali U. Erythrocytes sodium pump stimulation by ouabain and an endogenous ouabain-like factor. Cell Biochem Funct 25: 297-303, 2007.
24. Balzan S, Neglia D, Ghione S, D'Urso G, Baldacchino M, Montali U, L'Abbate A. Increased circulating levels of ouabain-like factor in patients with asymptomatic left ventricular dysfunction. Eur J Heart Fail 3: 165-171, 2001.
25. Balzan S, Nicolini G, Iervasi A, Di Cecco P, Fommei E. Endogenous ouabain and acute salt loading in low-renin hypertension. Am J Hypertens 18: 9006-9009, 2005.
26. Bauer N, Müller-Ehmsen J, Krämer U, Hambarchian N, Zobel C, Schwinger RHG, Neu H, Kirch U, Grünbaum EG, Schoner W. Ouabain-like compound changes rapidly upon physical exercise in man and dog: effects of β-blockade and ACE-inhibition. Hypertension 45: 1024-1028, 2005.
27. Berendes E, Cullen P, Van Aken H, Zidek W, Erren M, Hübschen M, Weber T, Wirtz S, Martin T, Walter M. Endogenous glycosides in critically ill patients. Crit Care Med 31: 1331-1337, 2003.
28. Bereta J, Cohen MC, Bereta M. Stimulatory effect of ouabain on VCAM-1 and iNOS expression in murine endothelial cells: involvement of NF-κB. FEBS Lett 377: 21-25, 1995.
29. Bers DM. Cardiac excitation-contraction coupling. Nature 415: 198-205, 2002.
30. Bianchi G. Genetic variations of tubular sodium reabsorption leading to "primary" hypertension: from gene polymorphism to clinical symptoms. Am J Physiol Regul Integr Comp Physiol 289: R1536-R1549, 2005.
31. Bianchi G, Tripodi G. Genetics of hypertension: the adducin paradigm. Ann NY Acad Sci 986: 660-668, 2003.
32. Bielawski K, Winnicka K, Bielawska A. Inhibition of DNA topoisomerases I and II and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol Pharm Bull 29: 1493-1497 2006.
33. Blanco G, Mercer RW. Isozymes of the Na-K ATPase: heterogeneity in structure, diversity in function. Am J Physiol Renal Physiol 275: F633-F650, 1998.
34. 2+ stores and cell responsiveness. Am J Physiol Cell Physiol 264: C1367-C1387, 1993.
35. Blaustein MP. Sodium ions, calcium ions, blood pressure regulation and hypertension: a reassessment and a hypothesis. Am J Physiol Cell Physiol 232: C167-C173, 1977.
36. Blaustein MP, Lederer WJ. Sodium/calcium exchange: its physiological implications. Physiol Rev 79: 763-854, 1999.
37. Blaustein MP, Zhang J, Chen L, Hamilton BC. How does salt retention raise blood pressure? Am J Physiol Regul Integr Comp Physiol 290: R514-R523, 2006.
38. Boulanger BR, Lilly MP, Hamlyn JM, Laredo J, Shurtleff D, Gann DS. Ouabain is secreted by the adrenal gland of the awake dog. Am J Physiol Endocrinol Metab 264: E413-E419, 1993.
39. Bova S, Blaustein MP, Ludens J, Harris D, DuCharme D, Hamlyn JM. Effect of an endogenous ouabainlike compound on heart and aorta. Hypertension 17: 944-950, 1991.
40. Braunwald E. Effects of digitalis on the normal and the failing heart. J Am Coll Cardiol 5: 51A-59A, 1985.
41. Briones AM, Xavier FE, Arribas SM, Gonzáles MC, Rossoni LV, Alonso MJ, Salaices M. Alterations in structure and mechanics of resistance arteries from ouabain-induced hypertensive rats. Am J Physiol Heart Circ Physiol 291: H193-H201, 2006.
42. Brophy JM. Rehabilitating digoxin. Eur Heart J 27: 127-129, 2006.
43. Budzikowski AS, Leenen FHH. Brain "ouabain" in the median preoptic nucleus mediates sodium-sensitive hypertension in spontaneously hypertensive rats. Hypertension 29: 599-605, 1997.
44. Cheung WJ, Kent MAH, ElShahat E, Wang H, Tan J, White R, Leenen FHH. Central and peripheral renin-angiotensin systems in ouabain-induced hypertension. Am J Physiol Heart Circ Physiol 291: H624-H630, 2006.
45. +-adenosine triphosphatase α-subunits in rat skeletal muscle. Endocrinology 142: 3474-3482, 2001.
46. +-ATPase is initiated by phosphorylation of Ser-18 in the rat a subunit and is responsible for the decreased activity in epithelial cells. J Biol Chem 274: 1920-1927, 1999.
47. Chueh S, Guh J, Chen Lai M, Teng C. Dual effects of ouabain on the regulation of proliferation and apoptosis in human prostatic smooth muscle cells. J Urol 66: 347-353, 2001.
48. +-ATPase relaxes cell attachment and sends a specific signal (NACos) to the nucleus. J Membr Biol 198: 147-158, 2004.
49. Contreras RG, Lazaro A, Mujica A, Gonzalez-Mariscal L, Valdes J, Garcia-Villegas M, Cereijido M. Ouabain resistance of the epithelial cell line (Ma104) is not due to lack of affinity of its pumps for the drug. J Membr Biol 145: 295-300, 1995.
50. +-ATPase and cell attachment. J Cell Sci 112: 4223-4232, 1999.
51. Crambert G, Haseler U, Beggah A, Yu C, Modyanov N, Horisberger J, Lelievre L, Geering K. Transport and pharmacological properties of nine different human Na,K-ATPase isoenzymes. J Biol Chem 275: 1976-1986, 2000.
52. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, Glorioso N, Lanzani C, Manunta P, Righetti M, Rivera R, Stella P, Troffa C, Zagato L, Bianchi G. Polymorphism of α-adducin and salt-sensitivity in patients with essential hypertension. Lancet 349: 1353-1357, 1997.
53. Dahl LK, Knudsen KD, Heine M, Leitl G. Effects of chronic excess salt ingestion. Genetic influence on the development of salt hypertension in parabiotic rats. Evidence for a circulating factor. J Exp Med 126: 687-699, 1967.
54. Daniel D, Süsal C, Kopp B, Opelz G, Terness P. Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives. Int Immunopharmacol 3: 1791-1801, 2003.
55. D'Amico M, Di Filippo C, Piegari E, Rinaldi B, Rossi F, Filippelli A. ETA endothelin receptors are involved in the ouabain-induced haemodynamic effects in the periaqueductal gray area of rats. Life Sci 72: 2211-2218, 2003.
56. Daniel EE, El-Yazbi A, Cho WJ. Caveolae and calcium handling, a review and a hypothesis. J Cell Mol Med 10: 529-544, 2006.
57. 2+-handling proteins? Am J Physiol Gastrointest Liver Physiol 281: G1101-G1114, 2001.
58. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997.
59. +-ATPase inhibitors derived from a 5α,14α- androstane scaffold as positive inotropic compounds. J Med Chem 46: 3644-3654, 2003.
60. Deutsch J, Jang HG, Mansur N, Ilovich O, Shpolansky U, Galili D, Feldman T, Rosen H, Lichtstein D. 4-(3′α,15β-dihydroxy- 5′β-estran-17′β-yl)furan-2-methyl alcohol: an anti-digoxin agent with a novel mechanism of action. J Med Chem 49: 600-606, 2006.
61. Devarajan P, Scaramuzzino D, Morrow J. Ankyrin binds to two distinct cytoplasmic domains of Na,K-ATPase α-subunit. Proc Natl Acad Sci USA 91: 2965-2969, 1994.
62. Devarajan P, Stabach PR, De Matteis MA, Morrow J. Na,K-ATPase transport from endoplasmic reticulum to Golgi requires the Golgi spectrin-ankyrin G119 skeleton in Madin Darby canine kidney cells. Proc Natl Acad Sci USA 94: 10711-10716, 1997.
63. Di Filippo C, Filippelli A, Rinaldi B, Piegari E, Esposito F, Rossi F, D'Amico M. Chronic peripheral ouabain treatment affects the brain endothelin system of rats. J Hypertens 21: 747-753, 2003.
64. DiBartolo V, Balzan S, Pieraccini L, Ghione S, Pegorana S, Biber P, Revoltella R, Montali U. Evidences for an ouabain-like immunoreactive factor in human newborn plasma coeluting with ouabain on HPLC. Life Sci 57: 1417-1425, 1995.
65. Dmitrieva RI, Bagrov AY, Lalli E, Sassone-Corsi P, Stocco DM, Doris PA. Mammalian bufadienolide is synthesized from cholesterol in the adrenal cortex by a pathway that is independent of cholesterol side-chain cleavage. Hypertension 36: 442-448, 2000.
66. Dmitrieva RI, Doris PA. Ouabain is a potent promoter of growth and activator of ERK1/2 in ouabain-resistant rat renal epithelial cells. J Biol Chem 278: 28160-28166, 2003.
67. Dolmetsch RE, Xu K, Lewis RS. Calcium oscillations increase the efficiency and specificity of gene expression. Nature 392: 933-936, 1998.
68. Dong XH, Komiyama Y, Nishimura N, Masuda M, Takahashi H. Nanomolar level of ouabain increases intracellular calcium to produce nitric oxide in rat aortic endothelial cells. Clin Exp Pharmacol Physiol 31: 276-283, 2004.
69. Doris PA, Hayward-Lester A, Bourne D, Stocco DM. Ouabain production by cultured adrenal cells. Endocrinology 137: 533-539, 1996.
70. +-ATPase and biological significance of their cardiac glycoside binding site. Am J Physiol Regul Integr Comp Physiol 290: R524-R528, 2006.
71. 2-isoform of Na,K-ATPase mediates ouabain-induced cardiac inotropy in mice. J Biol Chem 278: 53026-53034, 2003.
72. 2-isoform of Na-K-ATPase mediates ouabain-induced hypertension in mice and increased vascular contractility in vitro. Am J Physiol Heart Circ Physiol 288: H477-H485, 2005.
73. 1-isoform of Na,K-ATPase regulates cardiac contractility and functionally interacts and co-localizes with the Na/Ca exchanger in heart. J Biol Chem 279: 54053-54061, 2004.
74. Downward J. Signatures guide drug choice. Nature 439: 274-275, 2006.
75. Dulin BR, Krum H. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence. Curr Opin Cardiol 21: 393-399, 2006.
76. D'Urso G, Frascarelli S, Balzan S, Zucchi R, Umberto M. Production of ouabain-like factor in normal and ischemic rat heart. J Cardiovasc Pharmacol 53: 657-662, 2004.
77. D'Urso G, Frascarelli S, Balzan S, Zucchi R, Montali U. Production of ouabain-like factor in normal and ischemic rat heart. J Cardiovasc Pharmacol 43: 657-662, 2004.
78. Dutta S, Goswami S, Datta DK, Lindower JO, Marks BH. The uptake and binding of six radiolabeled cardiac glycosides by guinea-pig hearts and by isolated sarcoplasmic reticulum. J Pharmacol Exp Ther 164: 10-21, 1968.
79. Dutta S, Goswami S, Lindower JO, Marks BH. Subcellular distribution of digoxin-H3 in isolated guinea-pig and rat hearts. J Pharmacol Exp Ther 159: 324-334, 1968.
80. 1-subunit N-terminus during GPCR-dependent endocytosis. FEBS Lett 580: 5067-5070, 2006.
81. +-ATPase trafficking in response to GPCR signals and intracellular sodium. Circ Res 95: 1100-1108, 2004.
82. Ekinci FJ, Malik KU, Shea TB. Activation of the L voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to β-amyloid. J Biol Chem 274: 30322-30327, 1999.
83. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Genetics 7: 606-619, 2006.
84. +)-ATPase preparations from different tissues and species. Determination of kinetic constants and dissociation constants. Biochim Biophys Acta 307: 386-398, 1973.
85. Eva A, Kirch U, Scheiner-Bobis G. Signaling pathways involving the sodium pump stimulate NO production in endothelial cells. Biochim Biophys Acta 1758: 1809-1814, 2006.
86. Fedorova OV, Agalakova NI, Morrell CH, Lakatta EG, Bagrov AY. ANP differentially modulates marinobufagenin-induced sodium pump inhibition in kidney and aorta. Hypertension 48: 1160-1168, 2006.
87. Fedorova OV, Agalakova NI, Talan MI, Lakatta EG, Bagrov AY. Brain ouabain stimulates peripheral marinobufagenin via angiotensin II signalling in NaCl-loaded Dahl-S rats. J Hypertens 23: 1515-1523, 2005.
88. Fedorova OV, Bagrov AY. Inhibition of Na/K-ATPase from rat aorta by two endogenous Na/K pump inhibitors, ouabain and marinobufagenin. Evidence of interaction with different α-subunit isoforms. Am J Hypertens 10: 929-935, 1997.
89. Fedorova OV, Doris PA, Bagrov AY. Endogenous marinobufageninlike factor in acute volume expansion. Clin Exp Hypertens 20: 581-591, 1998.
90. 1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats. Hypertension 37: 462-466, 2001.
91. Fedorova OV, Kolodkin NI, Agalakova NI, Namikas AR, Bzhelyansky A, St-Louis J, Lakatta EG, Bagrov AY. Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intake. J Hypertens 23: 835-842, 2005.
92. Fedorova OV, Lakatta EG, Bagrov AY. Endogenous Na,K pump ligands are differentially regulated during acute NaCl loading of Dahl rats. Circulation 102: 3009-3014, 2000.
93. Fedorova OV, Talan MI, Agalakova NI, Lakatta EG, Bagrov AY. Coordinated shifts in Na/K-ATPase isoforms and their endogenous ligands during cardiac hypertrophy and failure in NaCl-sensitive hypertension. J Hypertens 22: 389-397, 2004.
94. 1 sodium pump, marinobufagenin, is a novel mediator of sodium chloride-dependent hypertension. Circulation 105: 1122-1127, 2002.
95. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, McTiernan C. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35: 537-544, 2000.
96. Ferrandi M, Manunta P, Balzan S, Hamlyn JM, Bianchi G, Ferrari P. Ouabain-like factor quantitation in mammalian tissues and plasma. Comparison of 2 independent assays. Hypertension 30: 886-896, 1997.
97. Ferrandi M, Minotti E, Salardi S, Florio M, Bianchi G, Ferrari P. Ouabain-like factor in Milan hypertensive rats. Am J Physiol Renal Fluid Electrolyte Physiol 263: F739-F748, 1992.
98. Ferrandi M, Molinari I, Barassi P, Minotti E, Bianchi G, Ferrari P. Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238. J Biol Chem 279: 33306-33314, 2004.
99. +-ATPase: relation to genetic hypertension. Am J Physiol Heart Circ Physiol 277: H1338-H1349, 1999.
100. Ferrari P, Ferrandi M, Tripoldi G, Torielli L, Padoani G, Minotti E, Melloni E, Bianchi G. PST 2238: a new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension. J Pharmacol Exp Ther 288: 1074-1083, 1999.
101. +-ATPase alterations in ouabain- and adducin-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 290: R529-R535, 2006.
102. Ferrari P, Torielli L, Ferrandi M, Padoani G, Duzzi L, Florio M, Conti F, Melloni L, Vesci L, Corsico N, Bianchi G. PST 2238: a new antihypertensive compound that antagonizes the long-term pressor effect of ouabain. J Pharmacol Exp Ther 285: 83-94, 1998.
103. Fitzgerald EM. Regulation of voltage-dependent calcium channels in rat sensory neurones involves a Ras-mitogen-activated protein kinase pathway. J Physiol 527: 433-444, 2000.
104. Frame MC, Fincham VJ, Carragher NO, Wyke AJ. v-Src's hold over actin and cell adhesions. Mol Cell Biol 3: 233-245, 2002.
105. Franco SJ, Huttenlocher A. Regulating cell migration: calpains make the cut. J Cell Sci 118: 3829-3838, 2005.
106. 1 sodium pump, is a marker of congestive heart failure severity. J Hypertens 20: 1189-1194, 2002.
107. Fujino M, Fujino S, Satoh K, Nakai T, Kado T. Physiological role and localization of the new ouabain receptor protein (31.5 kD) from cat cardiac muscles, using the monoclonal Ab against the protein. Adv Exp Med Biol 311: 449-451, 1992.
108. Gao J, Wymore RS, Wang Y, Gaudette GR, Krukenkamp IB, Cohen IS, Mathias RT. Isoform-specific stimulation of cardiac Na/K pumps by nanomolar concentrations of glycosides. J Gen Physiol 119: 297-312, 2002.
109. Gheorghiade M, Ferguson D. Digoxin: a neurohormone modulator in heart failure? Circulation 84: 2181-2186, 1991.
110. Gloor S, Antonicek H, Sweadner KJ, Pagliusi S, Frank R, Moos M, Schachner M. The adhesion molecule on glia (AMOG) is a homologue of the β-subunit of the Na,K-ATPase. J Cell Biol 110: 165-174, 1990.
111. Golden W, Martin L. Low-dose ouabain protects against excitotoxic apoptosis and up-regulates nuclear Bcl-2 in vivo. Neuroscience 137: 133-144, 2006.
112. Golomb E, Hill MR, Brown RG, Keiser HR. Ouabain enhances the mitogenic effect of serum in vascular smooth muscle cells. Am J Hypertens 7: 69-74, 1994.
113. 2+ signaling. Am J Physiol Cell Physiol 284: C475-C486, 2003.
114. +-ATPase by ouabain opens calcium channels coupled to acetylcholine release in guinea pig mesenteric plexus. J Neurochem 66: 1440-1447, 1996.
115. Goodlin RC. Antidigoxin antibodies in eclampsia. N Engl J Med 318: 518-519, 1988.
116. Goto A, Ishiguro T, Yamada K, Ishii M, Yoshioka M, Eguchi C, Shimura M, Sugimoto T. Isolation of an urinary digitalis-like factor indistinguishable from digoxin. Biochem Biophys Res Commun 173: 1093-1101, 1990.
117. Goto A, Yamada K. Ouabain-like factor. Curr Opin Nephrol Hypertens 7: 189-196, 1998.
118. Goto A, Yamada K. Purification of endogenous digitalis-like factors from normal human urine. Clin Exp Hypertens 20: 551-556, 1998.
119. Goto A, Yamada K, Nagoshi H, Terano Y, Omata M. Stress-induced elevation of ouabainlike compound in rat plasma and adrenal. Hypertension 26: 1173-1176, 1995.
120. Gotoh H, Kamiyama A, Shibayarna R, Sawada M, Kashimoto T. Involvement of phosphoinositide turnover in ouabain inotropism. Biochem Biophys Res Commun 194: 72-78, 1993.
121. Gottlieb SS, Rogowski AC, Weinberg M, Krichten CM, Hamilton BC, Hamlyn JM. Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 86: 420-425, 1992.
122. Greef K, Wirth KE. Pharmacokinetics of strophanthin glycosides. In: Handbook of Experimental Pharmacology. Berlin: Springer, 1981, vol. 56, pt. II, p. 57-85.
123. +-ATPase. J Biol Chem 275: 27832-27837, 2000.
124. +-ATPase and the epidermal growth factor receptor relays the signal from ouabain to mitogen-activated protein kinases. J Biol Chem 277: 18694-18702, 2002.
125. i. J Mol Cell Cardiol 29: 1615-1627, 1997.
126. Haddy FJ. Role of dietary salt in hypertension. Life Sci 79: 1585-1592, 2006.
127. Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Mandel F, Mathews WR, Ludens JH. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA 88: 6259-6263, 1991.
128. Hamlyn JM, Laredo J, Shah JR, Lu ZR, Hamilton BP. 11-Hydroxylation in the biosynthesis of endogenous ouabain: multiple implications. Ann NY Acad Sci 986: 685-693, 2003.
129. Hamlyn JM, Lu Z, Manunta P, Ludens JH, Kimura K, Shah JR, Laredo J, Hamilton JP, Hamilton MJ, Hamilton BP. Observations on the nature, biosynthesis, secretion and significance of endogenous ouabain. Clin Exp Hypertens 20: 523-533, 1998.
130. Hamlyn JM, Manunta P. Ouabain, digitalis like factors and hypertension. J Hypertens Suppl 10: S99-S111, 1992.
131. +-ATPase associated with essential hypertension. Nature 300: 650-652, 1982.
132. +-ATPase interaction with putative endogenous ouabain. Eur J Biochem 270: 1916-1919, 2003.
133. Haq S, Choukroun G, Kang Z, Ranu H, Matsui T, Rosenzweig A, Molkentin J, Alessandini A, Woodgett J, Hajjar R, Michael A, Force T. Glycogen synthase kinase 3β is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 151: 117-130, 2000.
134. Hara MR, Snyder SH. Cell signaling and neuronal death. Annu Rev Pharmacol Toxicol 47: 1.1-1.25, 2007.
135. Harris DW, Clark MA, Fisher JF, Hamlyn JM, Kolbasa KP, Ludens JH, Du Charme DW. Development of an immunoassay for endogenous digitalis like factor. Hypertension 17: 936-943, 1991.
136. Harwood SM, Allen DA, Raftery MJ, Yaqoob MM. Calpain is a mediator of myocardial injury in experimental uremia: is it activated by endogenous ouabain? Kidney Int 83: S177-S180, 2003.
137. Haux J. Digitalis: impinges on more than just the (ion) pump. Med Hypotheses 59: 781-782, 2002.
138. Haux J, Klepp O, Spigset O, Tretli S. Digitoxin medication and cancer: case control and internal dose response studies. BMC Cancer 1: 11, 2001.
139. Haux J, Lam M, Marthinsen A, Strickert T, Lundgren S. Digitoxin, in nontoxic concentrations, induces apoptotic cell death in Jurkat T cells in vitro. Z Onkol 31: 14-20, 1999.
140. Haux J, Solheim O, Isaksen T, Angelsen A. Digitoxin, in non-toxic concentrations, inhibits proliferation and induces cell death in prostate cancer cell lines. Z Onkol 32: 11-16, 2000.
141. +-ATPase play different roles in skeletal muscle contractility. Am J Physiol Regul Integr Comp Physiol 281: R917-R925, 2001.
142. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Mol Cell Biol 7: 589-600, 2006.
143. x sodium channels for the control of salt-intake behavior. J Neurosci 24: 9276-9281, 2004.
144. Hop VV, Ianosi-Irimie MR, Pridjian CA, Whitbred JM, Durst JM, Bagrov AY, Fedorova OV, Pridjian G, Puschett JB. Involvement of marinobufagenin in a rat model of human preeclampsia. Am J Nephrol 25: 520-528, 2005.
145. Höriger N, Zivanov D, Linde HH, Meyer K. Cardenolide hydrogen suberates and other bufadienolide hydrogen suberates in Ch'an Su. Helv Chim Acta 53: 1993-2002, 1970.
146. Huang BS, Amin MS, Leenen FHH. The central role of the brain in salt-sensitive hypertension. Curr Opin Cardiol 21: 295-304, 2006.
147. Huang BS, Cheung WJ, Wang H, Tan J, White RA, Leenen FH. Activation of the brain renin-angiotensin-aldosterone system by central sodium in Wistar rats. Am J Physiol Heart Circ Physiol 291: H1109-H1117, 2006.
148. + and ouabain are attenuated in transgenic rats deficient in brain angiotensinogen. Hypertension 37: 683-686, 2001.
149. Huang BS, Harmsen E, Yu H, Leenen FHH. Brain ouabain-like activity and the sympathoexcitatory and pressor effects of central sodium in rats. Circ Res 71: 1059-1066, 1992.
150. Huang BS, Huang X, Harmsen E, Leenen FHH. Chronic central versus peripheral ouabain, blood pressure, and sympathetic activity in rats. Hypertension 23: 1087-1090, 1994.
151. Huang BS, Kudlac M, Kumarathasan R, Leenen FH. Digoxin prevents ouabain and high salt intake-induced hypertension in rats with sinoaortic denervation. Hypertension 34: 733-738, 1999.
152. Huang BS, Leenen FHH. Both brain angiotensin II and "ouabain" contribute to sympathoexcitation and hypertension in Dahl S rats on high salt intake. Hypertension 32: 1028-1033, 1998.
153. Huang BS, Leenen FHH. Brain "ouabain" and angiotensin II in saltsensitive hypertension in spontaneously hypertensive rats. Hypertension 28: 1005-1012, 1996.
154. Huang BS, Leenen FHH. Brain "ouabain" mediates the sympathoexcitatory and hypertensive effects of high sodium intake in Dahl saltsensitive rats. Circ Res 74: 586-595, 1994.
155. Huang BS, Leenen FHH. Sympathoexcitatory and pressor responses to increased brain sodium and ouabain are mediated via brain angiotensin II. Am J Physiol Heart Circ Physiol 270: H275-H280, 1996.
156. +] precede the increases in blood pressure in Dahl S rats and SHR on high salt diet. Am J Physiol Heart Circ Physiol 287: H1160-H1166, 2004.
157. Huang BS, Wang H, Leenen FHH. Chronic central infusion of aldosterone leads to sympathetic hyperreactivity and hypertension in Dahl S but not Dahl R rats. Am J Physiol Heart Circ Physiol 288: H517-H524, 2005.
158. + in Dahl salt-sensitive vs.
159. Huang L, Kometiani P, Xie Z. Differential regulation of Na/K-ATPase α-subunit isoform gene expressions in cardiac myocytes by ouabain and other hypertrophic stimuli. J Mol Cell Cardiol 29: 3157-3167, 1997.
160. Huang L, Li H, Xie Z. Ouabain-induced hypertrophy in cultured cardiac myocytes is accompanied by changes in expression of several late response genes. J Mol Cell Cardiol 29: 429-4371, 1997.
161. Huang YT, Chueh SC, Teng CM, Guh JH. Investigation of ouabaininduced anticancer effect in human androgen-independent prostate cancer PC-3 cells. Biochem Pharmacol 67: 727-733, 2004.
162. Hulthen UL, Bolli P, Kiowski W, Bühler FR. Fore-arm vasoconstrictor response to ouabain: studies in patients with mild and moderate essential hypertension. J Cardiovasc Pharmacol 6: 75-81, 1984.
163. +-ATPase. Acta Physiol Scand 175: 165-171, 2002.
164. Ikeda U, Furuhashi K, Kanbe T, Shimada K. Ouabain enhances nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1β. Eur J Pharmacol 288: 379-383, 1995.
165. 2+ exchange (NCX1) inhibition by SEA0400. J Biol Chem 279: 7544-7553, 2004.
166. 2+ exchanger type-l in vascular smooth muscle. Nat Med 10: 1193-1199, 2004.
167. Jäger H, Wozniak G, Akintürk IH, Hehrlein FW, Scheiner-Bobis G. Expression of sodium pump isoforms and other sodium or calcium ion transporters in the heart of hypertensive patients. Biochim Biophys Acta 1513: 149-159, 2001.
168. 2 isoforms, a regulator of calcium in the heart. Mol Cell 3: 555-563, 1999.
169. Jing Y, Ohizumi H, Kawazoe N, Hashimoto S, Masuda Y, Nakajo S, Yishida T, Kuroiwa Y, Nakaya K. Selective inhibitory effect of bufalin on growth of human tumor cells in vitro: association with the induction of apoptosis in leukemia HL-60 cells. Jpn J Cancer Res 85: 645-651, 1994.
170. Jing Y, Watabe M, Hashimoto S, Nakajio S, Nakaya K. Cell cycle arrest and protein kinase modulating effect of bufalin on human leukemia ML1 cells. Anticancer Res 14: 1193-1198, 1994.
171. +-ATPase. J Biol Chem 270: 29971-29975, 1995.
172. 2+ exchanger in arteries: identification by immunoblotting and immunofluorescence microscopy. Am J Physiol Cell Physiol 266: C234-C242, 1994.
173. + pump low and high ouabain affinity α-subunit isoforms are differently distributed in cells. Proc Natl Acad Sci USA 94: 1800-1805, 1997.
174. Kajikawa M, Fujimoto S, Tsuura Y, Mukai E, Takeda T, Hamamoto Y, Takehiro M, Fujita J, Yamada Y, Seino Y. Ouabain suppresses glucose-induced mitochondrial ATP production and insulin release by generating reactive oxygen species in pancreatic islets. Diabetes 51: 2522-2529, 2002.
175. Kajimura S, Hirano T, Moriyama S, Vakkuri O, Leppaluoto J, Grau EG. Changes in plasma concentrations of immunoreactive ouabain in the tilapia in response to changing salinity: is ouabain a hormone in fish. Gen Comp Endocrinol 135: 90-99, 2004.
176. Kaplan JG. Membrane cation transport and the control of proliferation of mammalian cells. Annu Rev Physiol 40: 19-41, 1978.
177. Kawamura A, Guo J, Itagaki Y, Bell C, Wang Y, Haupert J, Garner T, Magil S, Gallagher RT, Berova N, Nakanishi K. On the structure of endogenous ouabain. Proc Natl Acad Sci USA 96: 6654-6659, 1999.
178. Kawamura A, Guo J, Maggiali F, Berova N, Nakanishi K. Structure of endogenous ouabain. Pure Appl Chem 71: 1643-1648, 1999.
179. + ions. J Biochem (Tokyo) 126: 278-286, 1999.
180. Kawazoe N, Watabe M, Masuda Y, Nakajo S, Nakaya K. Tiam1 is involved in the regulation of bufalin-induced apoptosis in human leukemia cells. Oncogene 8: 13-21, 1999.
181. +-ATPase digitalis binding site. J Mol Graph Model 23: 465-475, 2005.
182. Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S, Kahaleh MB, Xie Z, Malhotra D, Kolodkin NI, Lakatta EG, Feodorova OV, Bagrov AY, Shapiro JI. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 47: 488-495, 2006.
183. 1-subunit. J Biol Chem 279: 17418-17427, 2004.
184. Khundmiri SJ, Metzler MA, Ameen M, Amin V, Rane MJ, Delamere NA. Ouabain induces cell proliferation through calcium-dependent phosphorylation of Akt (protein kinase B) in opossum kidney proximal tubule cells. Am J Physiol Cell Physiol 291: C1247-C1257, 2006.
185. Kim L, Kimmel AR. GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin Genet Dev 10: 508-514, 2000.
186. Kimura K, Manunta P, Hamilton BP, Hamlyn JM. Different effects of in vivo ouabain and digoxin on renal artery function and blood pressure in rats. Hypertens Res 23 Suppl: S67-S76, 2000.
187. Kitano S, Morimoto S, Nishibe A, Fukuo K, Hirotani A, Nakahashi T, Ysuda O, Ogihara T. Exogenous ouabain is accumulated in the adrenals and mimics the kinetics of endogenous digitalis-like factor in rats. Hypertens Res 21: 47-56, 1998.
188. Kochsiek K. Importance of serum glycoside concentrations. In: Cardiac Glycosides 1785-1985, edited by Erdmann E, Greef K, and Skou JC. New York: Springer, 1986, p. 407-416.
189. +-ATPase to growth-related genes in cardiac myocytes. The roles of Ras and mitogen-activated protein kinases. J Biol Chem 273: 15249-15256, 1998.
190. +-ATPase in human breast cancer cells. Mol Pharmacol 67: 929-936, 2005.
191. 1-subunit gene expression by ouabain and other hypertrophic stimuli in neonatal rat cardiac myocytes. Mol Cell Biochem 215: 65-72, 2000.
192. Komiyama Y, Dong XH, Nishimura N, Masaki H, Yoshika M, Masuda M, Takahashi H. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure. Clin Biochem 38: 36-45, 2005.
193. Komiyama Y, Nishimura N, Munakata M, Mori T, Okuda K, Nishino N, Hirose S, Kosaka C, Masuda M, Takahashi H. Identification of endogenous ouabain in culture supernatant of PC12 cells. J Hypertens 19: 229-236, 2001.
194. Komiyama Y, Nishimura N, Munakata M, Okuda K, Nishino N, Kosaka C, Masuda M, Mori T, Matsuda T, Takahashi H. Increases in plasma ouabainlike immunoreactivity during surgical extirpation of pheochromocytoma. Hypertens Res 22: 135-139, 1999.
195. +-ATPase in kidney epithelial cells. Eur J Cell Biol 45: 230-237, 1987.
196. Kotova O, Al-Khalili L, Talia S, Hooke C, Fedorova OV, Bagrov AY, Chibalin AV. Cardiotonic steroids stimulate glycogen synthesis in human skeletal muscle cells via a Src- and ERK1/2-dependent mechanism. J Biol Chem 281: 20085-20094, 2006.
197. Kurosawa M, Numazawa S, Tani Y, Yoshida T. ERK signaling mediates the induction of inflammatory cytokines by bufalin in human monocytic cells. Am J Physiol Cell Physiol 278: C500-C508, 2000.
198. Kurosawa M, Tani Y, Nishimura S, Numazawa S, Yoshida T. Distinct PKC isozymes regulate bufalin-induced differentiation and apoptosis in human monocytic cells. Am J Physiol Cell Physiol 280: C459-C464, 2001.
199. LaMarca HL, Morris CA, Pettit GR, Nagowa T, Puschett JB. Marinobufagenin impairs first trimester cytotrophoblast differentiation. Placenta 27: 984-988, 2006.
200. + concentration is an early event in murine erythroleukemic cell differentiation. J Biol Chem 260: 7322-7324, 1985.
201. Lanzani C, Citterio L, Jankaricova M, Sciarrone MT, Barlassina C, Fattoria S, Messaggioa E, Di Serio C, Zagato L, Cusi D, Hamlyn JM, Stella A, Bianchi G, Manunta P. Role of the adducin family genes in human essential hypertension. J Hypertens 23: 543-549, 2005.
202. Laredo J, Hamilton BP, Hamlyn JM. Ouabain is secreted by bovine adrenocortical cells. Endocrinology 135: 794-797, 1994.
203. Laredo J, Hamilton JP, Hamlyn JM. Secretion of endogenous ouabain from bovine adrenal cells. Role of zona glomerulosa and zona fasciculata. Biochem Biophys Res Commun 212: 487-493, 1995.
204. 1- Adrenergic receptors stimulate secretion of endogenous ouabain from human and bovine adrenocortical cells. In: Na/K-ATPase and Related ATPases, edited by Taniguchi K and Kayas S. Amsterdam: Elsevier Science, 2000, p. 671-679.
205. Laredo J, Shah JR, Lu Z, Hamilton BP, Hamlyn JM. Angiotensin II stimulates secretion of endogenous ouabain from bovine adrenal cortical cells via angiotensin II receptors. Hypertension 29: 401-107, 1997.
206. Larre I, Ponce A, Fiorentino R, Shoshani L, Contreras RG, Cereijido M. Contacts and cooperation between cells depend on the hormone ouabain. Proc Natl Acad Sci USA 103: 10911-10916, 2006.
207. Lebart MC, Benyamin Y. Calpain involvement in the remodeling of cytoskeletal anchorage complexes. FEBS Lett 273: 3415-3426, 2006.
208. Lecuona E, Ridge K, Pesce L, Batlle D, Sznajder JI. The GTP-binding protein RhoA mediates Na,K ATPase exocytosis in alveolar epithelial cells. Mol Biol Cell 14: 3888-3897, 2003.
209. 2+ sensor. Proc Natl Acad Sci USA 103: 13232-13237, 2006.
210. Leenen FHH, Harmsen E, Yu H. Dietary sodium and central vs. peripheral ouabain-like activity in Dahl salt-sensitive vs. salt-resistant rats. Am J Physiol Heart Circ Physiol 267: H1916-H1920, 1994.
211. Leenen FHH, Harmsen E, Yu H, Yuan B. Dietary sodium stimulates ouabainlike activity in adrenalectomized spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 265: H421-H424, 1993.
212. Le Grand B, Deroubais E, Coulombe A, Coraboeuf E. Stimulatory effects of ouabain on T- and L-type calcium currents in guinea pig cardiac myocytes. Am J Physiol Heart Circ Physiol 258: H1620-H1623, 1990.
213. Li J, Zelenin S, Aperia A, Aizman O. Low doses of ouabain protect from serum deprivation-triggered apoptosis and stimulate kidney cell proliferation via activation of NF-κB. J Am Soc Nephrol 17: 1848-1857, 2006.
214. Li SQ, Eim C, Kirch U, Lang RE, Schoner W. Bovine adrenals and hypothalamus are a major source of proscillaridin A- and ouabain- immunoreactivities. Life Sci 62: 1023-1033, 1998.
215. +-ATPase. Toxicol Appl Pharmacol 151: 377-384, 1998.
216. Liang M, Cai T, Tian J, Qu W, Xie ZJ. Functional characterization of Src-interacting Na/K-ATPase using RNA interference assay. J Biol Chem 281: 19709-19719, 2006.
217. Lichtstein D, Gati I, Samuelov S, Berson D, Rozeman Y, Landau L, Deutsch J. Identification of digitalis-like compounds in human cataractous lenses. Eur J Biochem 216: 261-268, 1993.
218. Lichtstein D, Steinitz M, Gati I, Samuelov S, Deutsch J, Orly J. Biosynthesis of digitalis-compound in rat adrenal cells: hydroxycholesterol as a precursor. Life Sci 62: 2109-2126, 1998.
219. Lin H, Juang JL, Wang PS. Involvement of Cdk5/p25 in digoxintriggered prostate cancer cell apoptosis. J Biol Chem 279: 29302-29307, 2004.
220. Liu J, Kesirv R, Periyasamy S, Malhotra B, Shapiro J. Ouabain induces endocytosis of plasmalemmal Na/K-ATPase in LLC-PKI cells by a clathrin-dependent mechanism. Kidney Int 66: 227-241, 2004.
221. Liu J, Liang M, Liu L, Malhotra D, Xie Z, Shapiro JI. Ouabain-induced endocytosis of plasmalemmal Na/K-ATPase in LLC-PK1 cells requires caveolin-1. Kidney Int 67: 1844-1854, 2005.
222. 2+ concentrations. J Biol Chem 275: 27838-27844, 2000.
223. +-ATPase. Am J Physiol Cell Physiol 284: C1550-C1560, 2003.
224. Liu XL, Miyakawa A, Aperia A, Krieger P. Na,K-ATPase generates calcium oscillations in hippocampal astrocytes. Neuroreport 18: 597-600, 2007.
225. Lopatin DA, Ailamazian EK, Dmitrieva RI, Shpen VM, Fedorova OV, Doris PA, Bagrov AY. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens 17: 1179-1187, 1999.
226. López-Lázaro M, Pastor N, Azrak SS, Ayuso MJ, Austin CA, Cortés F. Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J Nat Prod 68: 1642-1645, 2005.
227. López-Lázaro M, Pastor N, Azrak SS, Ayuso MJ, Cortés F, Austin CA. Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells. Leuk Res 30: 895-898, 2006.
228. MacGregor G, Fenton S, Alaghband-Zadeh J, Markandu N, Roulston J, deWardener H. An increase in circulating inhibitor of Na,K-dependent ATPase: a possible link between salt intake and the development of hypertension. Clin Sci (Lond) 61: 17s-20s, 1981.
229. Magyar CE, Wang JN, Azuma KK, McDonough AA. Reciprocal regulation of cardiac Na-K-ATPase and Na/Ca exchanger: hypertension, thyroid hormone, development. Am J Physiol Cell Physiol 269: C675-C682, 1995.
230. Malawista I, Davidson AE. Isolation and identification of rhamnose from rabbit skin. Nature 192: 871-872, 1961.
231. 2-terminal kinase. Cancer Res 60: 3838-3847, 2000.
232. Manna SK, Sreenivasan Y, Sarkar A. Cardiac glycoside inhibits IL-8-induced biological responses by downregulating IL-8 receptors through altering membrane fluidity. J Cell Physiol 207: 195-207, 2006.
233. Manunta P, Evans G, Hamilton BP, Gann D, Resau J, Hamlyn JM. A new syndrome with elevated plasma ouabain and hypertension secondary to an adrenocortical tumor (Abstract). J Hypertens 10: S27, 1992.
234. Manunta P, Ferrandi M. Cardiac glycosides and cardiomyopathy. Hypertension 47: 343-344, 2006.
235. Manunta P, Ferrandi M. Different effects of marinobufagenin and endogenous ouabain. J Hypertens 257: 257-259, 2004.
236. Manunta P, Hamilton BP, Hamlyn JM. Salt intake and depletion increase circulating levels of endogenous ouabain in normal men. Am J Physiol Regul Integr Comp Physiol 290: R553-R559, 2006.
237. Manunta P, Hamilton BP, Hamlyn JM. Structure-activity relationship for hypertensinogenic activity of ouabain. Role of the sugar and lactone ring. Hypertension 37: 472-477, 2001.
238. Manunta P, Hamilton J, Rogowski AC, Hamilton BP, Hamlyn JM. Chronic hypertension induced by ouabain but not digoxin in the rat: antihypertensive effect of digoxin and digitoxin. Hypertens Res 23: S77-S85, 2000.
239. Manunta P, Iacoviello M, Forleo C, Messaggio E, Hamlyn JM, Lucarelli K, Guida P, Romito R, De Tommasi E, Bianchi G, Rizzon P, Pitzalis MV. High circulating levels of endogenous ouabain in the offspring of hypertensive and normotensive individuals. J Hypertens 23: 1677-1681, 2005.
240. Manunta P, Messagio E, Ballabeni C, Sciarrone MT, Lanzani C, Ferrandi M, Hamlyn JM, Cusi D, Galletti F, Bianchi G, for the Salt Sensitivity Study Group of the Italian Society of Hypertension. Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension. Hypertension 38: 198-203, 2001.
241. Manunta P, Rogowski AC, Hamilton BP, Hamlyn JM. Ouabain-induced hypertension in the rat: relationships among plasma and tissue ouabain and blood pressure. J Hypertens 12: 549-560, 1994.
242. Manunta P, Stella P, Rivera R, Ciurlino D, Cusi D, Ferrandi M, Hamlyn JM, Bianchi G. Left ventricular mass, stroke volume and ouabain-like factor in essential hypertension. Hypertension 34: 450-456, 1999.
243. Marbán E. Cardiac channelopathies. Nature 415: 213-218, 2002.
244. Marbán E, Tsien RW. Enhancement of calcium current during digitalis inotropy in mammalian heart: positive feed-back regulation by intracellular calcium? J Physiol 329: 589-614, 1982.
245. Masuda Y, Kawazoe N, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K. Bufalin induces apoptosis and influences the expression of apoptosis-related genes in human leukemia cells. Leuk Res 19: 549-556, 1995.
246. Masugi F, Ogihara T, Hasegawa T, Sagakuchi K, Kumahara Y. Normalization of high plasma level of ouabain-like immunoreactivity in primary aldosteronism after removal of adenoma. J Hum Hypertens 2: 17-20, 1988.
247. Mathews WR, DuCharme DW, Hamlyn JM, Harris DW, Mandel F, Clark MA, Ludens JA. Mass spectral characterization of an endogenous digitalis like factor from human plasma. Hypertension 17: 930-935, 1991.
248. Matsumori A, Ono K, Nishio R, Igata H, Shioi T, Matsui S, Furukawa Y, Wasaki AI, Nose Y, Sasayama S. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation 96: 1501-1506, 1997.
249. 2+ increases and apoptosis in androgen independent, metastatic human prostate adenocarcinoma cells. Cancer Res 60: 3807-3812, 2000.
250. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure. N Engl J Med 26: 1441-1446, 1971.
251. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol Regul Integr Comp Physiol 274: R577-R595, 1998.
252. Micheletti R, Mattera GG, Rocchetti M, Schiavone A, Loi MF, Zaza A, Gagnol RJP, De Munari S, Melloni P, Carminati P, Bianchi G, Ferrari P. Pharmacological profile of the novel inotropic agent (E,Z)-3-[(2- aminoethoxy)imino]androstane-6,17-dione hydrochloride (PST2744). J Pharmacol Exp Ther 303: 592-600, 2002.
253. Michlig S, Mercier A, Doucet A, Schild L, Horisberger JD, Rossier BC, Firsov D. ERK1/2 controls Na,K-ATPase activity and transepithelial sodium transport in the principal cell of the cortical collecting duct of the mouse kidney. J Biol Chem 279: 51002-51012, 2004.
254. Mijatovic T, Mathieu V, Gaussin JF, De Nève N, Ribaucour F, Van Quaquebeke E, Dumont P, Darro F, Kis R. Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia 8: 402-412, 2006.
255. Mijatovic T, Op De Beeck A, Van Quaquebeke E, Dewelle J, Darro F, de Launoit Y, Kiss R. The cardenolide UNBS1450 is able to deactivate nuclear factor κB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol Cancer Ther 5: 391-399, 2006.
256. Miyakawa-Naito A, Uhlén P, Lal M, Aizman O, Mikoshiba K, Brismar H, Zelenin S, Aperia A. Cell signaling microdomain with Na,K-ATPase and inositol 1,4,5-triphosphate receptor generates calcium oscillations. J Biol Chem 318: 50355-50361, 2003.
257. +-ATPase to ERK1/2. J Biol Chem 276: 42050-42056, 2001.
258. +-ATPase to ERK1/2. J Cardiovasc Pharmacol 41: 609-614, 2003.
259. Mohler PJ, Bennett V. Ankyrin-based cardiac arrhythmias: a new class of channelopathies due to loss of cellular targeting. Curr Opin Cardiol 20: 189-193, 2005.
260. 2+ in the heart: contraction versus intracellular signaling. J Clin Invest 116: 623-626, 2006.
261. + pump and sarcoplasmic reticulum in smooth muscle. Nature 365: 657-660, 1993.
262. Moreth K, Kuske R, Renner D, Schoner W. Blood pressure in essential hypertension correlates with the concentration of a circulating inhibitor of the sodium pump. Klin Wochenschr 64: 239-244, 1986.
263. Morrow JS, Cianci CD, Ardito T, Mann AS, Kashgarian M. Ankyrin links fodrin to the α-subunit of Na,K-ATPase in Madin-Darby canine kidney cells and in intact renal tubule cells. J Cell Biol 108: 455-465, 1989.
264. Msuda Y, Kawazoe N, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K. Bufalin induces apoptosis and influences the expression of apoptosis-related genes in human leukemia cells. Leuk Res 19: 549-556, 1995.
265. 1 when expressed separately in yeast cells. Am J Physiol Cell Physiol 281: C1355-C1364, 2001.
266. Müller-Ehmsen J, Nickel J, Zobel C, Hirsch I, Bölck B, Brixius K, Schwinger RHG. Longer term effects of ouabain on the contractility of rat isolated cardiomyocytes and on the expression of Ca and Na regulating proteins. Basic Res Cardiol 98: 90-96, 2003.
267. Müller-Ehmsen J, Wang J, Schwinger R, McDonough A. Region specific regulation of sodium pump isoform and Na,Ca-exchanger expression in the failing human heart - right atrium vs. left ventricle. Cell Mol Biol (Noisy-le-grand) 47: 373-381, 2001.
268. 1, promotes neurite outgrowth. J Biol Chem 268: 26260-26267, 1993.
269. i transient in cardiomyocytes. J Mol Cell Cardiol 31: 237-245, 1999.
270. Murrell JR, Randall JD, Rosoff J, Zhao JL, Jensen RV, Gullans SR, Haupert J. Endogenous ouabain: upregulation of steroidogenic genes in hypertensive hypothalamus but not adrenal. Circulation 112: 1301-1308, 2005.
271. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309, 2005.
272. 1 cell cycle arrest of endometriotic stromal cells: a promising agent for the treatment of endometriosis. Mol Hum Reprod 11: 817-823, 2005.
273. +-ATPase, ankyrin, and fodrin in Madin-Darby canine kidney (MDCK) cells: implications for the biogenesis of epithelial cell polarity. J Cell Biol 108: 893-902, 1989.
274. Neri G, De Toni R, Tortorella C, Rebuffat P, Bova S, Cargnelli G, Petrelli L, Spinazzi R, Nussdorfer GG. Ouabain chronic infusion enhances the growth and steroidogenic capacity of rat adrenal zona glomerulosa: the possible involvement of the endothelin system. Int J Mol Med 18: 315-319, 2006.
275. Newman RA, Yanq P, Hittelman WN, Lu T, Ho DH, Ni D, Chan D, Vijjeswarapu M, Cartwriqht C, Felix E, Addington C. Oleandrin-mediated oxidative stress in human melanoma cells. J Exp Ther Oncol 5: 167-181, 2006.
276. Noble D. Mechanism of action of therapeutic levels of cardiac glycosides. Cardiovasc Res 14: 495-514, 1980.
277. Numazawa S, Honma Y, Yamamoto T, Yoshida T, Kuroiwa Y. A cardiotonic steroid bufalin-like factor in human plasma induces leukemia cell differentiation. Leuk Res 19: 945-953, 1995.
278. +-ATPase inhibition in the early changes in proto-oncogene expression. Biochem Pharmacol 52: 321-329, 1996.
279. +-ATPase inhibition in K562 cell differentiation induced by bufalin. J Cell Physiol 160: 113-120, 1994.
280. Núnez-Duran H, Atonal F, Contreras P, Melendez E. Endocytosis inhibition protects the isolated guinea pig heart against ouabain toxicity. Life Sci 58: 193-198, 1996.
281. Núnez-Durán H, Fernández P. Evidence for an intracellular site of action in the heart for two hydrophobic cardiac steroids. Life Sci 74: 1337-1344, 2004.
282. Oda M, Kurosawa M, Numazawa S, Tanaka S, Akizawa T, Ito K, Maeda M, Yoshida T. Determination of bufalin-like immunoreactivity in serum of humans and rats by time-resolved fluoroimmunoassay for using a monoclonal antibody. Life Sci 68: 1107-1117, 2001.
283. Orlov SN, Hamet P. Intracellular monovalent ions as second messengers. J Membr Biol 210: 161-172, 2006.
284. + ratio blocks apoptosis in vascular smooth muscle at a site upstream of caspase. J Biol Chem 274: 16545-16552, 1999.
285. i. Pflügers Arch 448: 335-345, 2004.
286. Ozawa Y, Houchi H, Teraoka K, Azuma M, Kamimura T, Yoshizumi M, Tsuchiya K, Tamaki T, Minakuchi K. Long-term regulation of catecholamine formation by ouabain in cultured bovine adrenal chromaffin cells. J Cardiovasc Pharmacol 36 Suppl 2: S15-S18, 2000.
287. Pacheco ME, Marin J, Manso AM, Rodriguez-Martinez MA, Briones A, Salaices M, Redondo J. Nitric oxide synthase induction by ouabain in vascular smooth muscle cells from normotensive and hypertensive rats. J Hypertens 18: 877-884, 2000.
288. Paganelli F, Maixent JM, Gélisse R, Barnay P, Dodero F, Francheschi F, Lévy S, Saadjian A. Effect of digoxin on chemoreflex in patients with chronic heart failure. Cell Mol Biol (Noisy-le-grand) 47: 335-340, 2001.
289. Pamnani M, Burris J, Jemionek JF, Huot S, Price M, Freis E, Haddy FJ. Humoral Na-K pump inhibitory activity in essential hypertension and in normotensive subjects after acute volume expansion. Am J Hypertens 2: 524-531, 1989.
290. Pamnani MB, Chen S, Yuan CM, Haddy FJ. Chronic blood pressure effects of bufalin, a sodium-potassium ATPase inhibitor in rats. Hypertension 23: I-106 -I-109, 1994.
291. Paulus WJ. How are cytokines activated in heart failure? Eur J Heart Fail 1: 309-312, 1999.
292. 2+-dependent expression of early response genes in cardiac myocytes. J Biol Chem 271: 10372-10378, 1996.
293. Periyasamy SM, Liu J, Tanta F, Kabak B, Wakefield B, Malhotra D, Kennedy DJ, Nadoor A, Fedorova OV, Gunning W, Xie Z, Bagrov AY, Shapiro JI. Salt loading includes redistribution of the plasmalemmal Na/K-ATPase in proximal tubule cells. Kidney Int 67: 1868-1877, 2005.
294. Perrin A, Brasmes B, Chambaz EM, Defaye G. Bovine adrenocortical cells in culture synthesize an ouabain-like compound. Mol Cell Endocrinol 126: 7-15, 1997.
295. S6k. Am J Physiol Lung Cell Mol Physiol 285: L802-L807, 2003.
296. Pidgeon GB, Richards AM, Nicholls MG, Lewis LK, Yandle TG. Acute effects of intravenous ouabain in healthy volunteers. Clin Sci (Lond) 86: 391-397, 1994.
297. Pierdomenico SD, Bucci A, Manunta P, Rivera R, Ferrandi M, Hamlyn JM, Lapenna D, Cuccurullo F, Mezzetti A. Endogenous ouabain and hemodynamic and left ventricular geometric patterns in essential hypertension. Am J Hypertens 14: 44-50, 2001.
298. Pitzalis MV, Hamlyn JM, Messaggio E, Iacoviello M, Forleo C, Romito R, de Tommasi E, Rizzon P, Bianchi G, Manunta P. Independent and incremental prognostic value of endogenous ouabain in idiopathic dilated cardiomyopathy. Eur J Heart Fail 8: 179-186, 2006.
299. Poston L, Sewell R, Wilkinson S, Richardson P, Williams R, Clarkson E, MacGregor G, DeWardener H. Evidence for a circulating sodium transport inhibitor in essential hypertension. Br Med J 282: 847-849, 1981.
300. Qazzaz HMAM, Cao Z, Bolanowski DD, Clark BJ, Valdes R Jr. De novo biosynthesis and radiolabeling of mammalian digitalis-like factors. Clin Chem 50: 612-620, 2004.
301. Qazzaz HMAM, El-Masri MA, Valdes RJ. Secretion of a lactone-hydrogenated ouabain-like effector of sodium, potassium-adenosine triphosphatase activity by adrenal cells. Endocrinology 141: 3200-3209, 2000.
302. Qazzaz HMAM, Goudy SL, Valdes RJ. Deglycosylated products of endogenous digoxin-like immunoreactive factor in mammalian tissue. J Biol Chem 271: 8731-8737, 1996.
303. Qazzaz HMAM, Lane AN, Valdes RJ. Structural identification of digoxin-like factors (DLIFs) using NMR spectroscopy (Abstract). Clin Chem 49 Suppl 6: A130, 2003.
304. Qiu LY, Krieger E, Schaftenaar G, Swarts HGP, Willems PHGM, De Pont JJHHM, Koenderink JB. Reconstruction of the complete ouabain-binding pocket of Na,K-ATPase in gastric H,K-ATPase by substitution of only seven amino acids. J Biol Chem 280: 32349-32355, 2005.
305. Quadri L, Bianchi G, Cerri A, Fedrizzi G, Ferrari P, Gobbini M, Melloni P, Sputore S, Torri M. 17β-(3-furyl)-5β-androstane- 3β-14β-17α-triol (PST 2238). A very potent antihypertensive agent with a novel mechanism of action. J Med Chem 40: 1561-1564, 1997.
306. Ramirez-Ortega M, Maldonado-Lagunas V, Melendez-Zajgla J, Carrillo-Hemandez J, Pastelin-Henandez G, Picazo-Picazo, Ceballos-Reyes G. Proliferation and apoptosis of HeLa cells induced by in vitro stimulation with digitalis. Eur J Pharmacol 534: 71-76, 2006.
307. Raynaud F, Marcilhac A. Implication of calpain in neuronal apoptosis: a possible regulation of Alzheimer's disease. FEBS Lett 273: 3437-3443, 2006.
308. Reichstein T. Cardenolid und Pregnanglykoside. Naturwissenschaften 3: 53-76, 1967.
309. Ren YP, Huang RW, Lü ZR. Ouabain at pathological concentrations might induce damage in human vascular endothelial cells. Acta Pharmacol Sin 27: 165-172, 2006.
310. 2+ exchanger is essential for the action of cardiac glycosides. Circ Res 90: 305-308, 2002.
311. 2+ exchange in the regulation of cardiac excitation-contraction coupling. Cardiovasc Res 67: 198-207, 2005.
312. Ringer S. Regarding the influence of the organic constituents of the blood on the contractility of the ventricle. J Physiol 6: 361-381, 1885.
313. + pump inhibition: evaluation of electrophysiological mechanisms. J Pharmacol Exp Ther 305: 765-771, 2003.
314. + pump inhibitors with different toxicity: digoxin and PST2744 [(E,Z)-3-((2-aminoethoxy)imino)androstane- 6,17-dione hydrochloride]. J Pharmacol Exp Ther 313: 207-215, 2005.
315. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 415: 206-212, 2002.
316. Ron D, Kasanitz MG. New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J 13: 1658-1676, 1999.
317. Rosen H, Glukhman V, Feldmann T, Fridman E, Lichtstein D. Cardiac steroids induce changes in recycling of the plasma membrane in human NT2 cells. Mol Biol Cell 15: 1044-1054, 2004.
318. Rossi GP, Manunta P, Hamlyn JM, Pavan E, De Toni R, Semplicini A, Pessina AC. Immunoreactive endogenous ouabain in primary hyper-aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels. J Hypertens 13: 1181-1191, 1995.
319. Rossoni L, Salaices M, Miguel M, Briones A, Barker L, Vassallo D, Alonso M. Ouabain-induced hypertension is accompanied by increases in endothelial vasodilator factors. Am J Physiol Heart Circ Physiol 283: H2110-H2118, 2002.
320. Rossoni LV, Cunha V, Franca A, Vasallo DV. The influence of nanomolar ouabain on vascular pressor responses is modulated by the endothelium. J Cardiovasc Pharmacol 34: 887-982, 1999.
321. Rossoni LV, dos Santos L, Barker LA, Vassallo DV. Ouabain changes arterial blood pressure and vascular reactivity to phenylephrine in L-NAME-induced hypertension. J Cardiovasc Pharmacol 41: 105-116, 2003.
322. +-ATPase activity and expression in hypertension induced by chronic administration of ouabain. Br J Pharmacol 135: 771-781, 2002.
323. +-ATPase in ouabain-induced hypertension. Br J Pharmacol 135: 771-781, 2002.
324. + pump in fibroblast mitogenesis. In: Monovalent Cations in Biological Systems, edited by Pasternak CA. Boca Raton, FL: CRC, 1990, p. 303-319.
325. Sagawa T, Sagawa K, Kelly JE, Tsushima RG, Wasserstrom JA. Activation of cardiac ryanodine receptors by cardiac glycosides. Am J Physiol Heart Circ Physiol 282: H1118-H1126, 2002.
326. Sánchez-Ferrer C, Fernández-Alfonso M, Ponte A, Casado M, Gonzales R, Rodriguez-Manas L, Pereja A, Marin J. Endothelial modulation of the ouabain-induced contraction of human placental vessels. Circ Res 71: 943-950, 1992.
327. + channels: slip-mode conductance. Science 279: 1027-1033, 1998.
328. Satoh E, Nakazato Y. On the mechanism of ouabain-induced release of acetylcholine from synaptosomes. J Neurochem 58: 1038-1044, 1992.
329. Saunders R, Scheiner-Bobis G. Ouabain stimulates endothelin release and expression in human endothelial cells without inhibiting the sodium pump. Eur J Biochem 271: 1054-1062, 2004.
330. Scheiner-Bobis G, Schoner W. A fresh facet for ouabain action. Nat Med 7: 1288-1289, 2001.
331. Schiebinger RJ, Cragoe EJ, Jr. Ouabain. A stimulator of atrial natriuretic peptide secretion and its mechanism of action. Circ Res 72: 1035-1043, 1993.
332. 1 subunits assemble to functional sodium pumps in Xenopus oocytes. J Biol Chem 267: 20212-20216, 1992.
333. Schneider R, Wray V, Nimtz M, Lehmann WD, Kirch U, Antolovic R, Schoner W. Bovine adrenals contain, in addition to ouabain, a second inhibitor of the sodium pump. J Biol Chem 273: 784-792, 1998.
334. Schoner W. Endogenous cardiac glycosides, a new class of steroid hormones. Eur J Biochem 269: 2440-2448, 2002.
335. 2+ signalling - new faces in the line up. Curr Mol Med 4: 313-322, 2004.
336. +-channel activators. Am Heart J 131: 988-993, 1996.
337. Schwinger RH, Bubdgaard H, Müller-Ehmsen J, Kjeldsen K. The Na, K-ATPase in the failing human heart. Cardiovasc Res 57: 913-920, 2003.
338. 2+ exchanger protein levels in human heart failure. Circulation 99: 2105-2112, 1999.
339. Sekine Y, Takeda K, Ichijo H. The ASK1-MAP kinase signaling in ER stress and neurodegenerative diseases. Curr Mol Med 6: 87-97, 2006.
340. Shamraj O, Grupp I, Grupp G, Melvin D, Gradoux N, Kremers W, Linqrel J, De Pover A. Characterization of Na/K-ATPase, its isoforms, and the inotropic response to ouabain in isolated failing hearts. Cardiovasc Res 72: 2229-22237, 1993.
341. Shiratsuchi A, Nakanishi Y. Phosphatidylserine-mediated phygocytosis of anticancer drug-treated cells by macrophages. J Biochem (Tokyo) 126: 1101-1106, 1999.
342. +-ATPase in epithelia depends on the association between β-subunits located in neighboring cells. Mol Biol Cell 16: 1071-1081, 2005.
343. Sich B, Kirch U, Tepel M, Ziedek W, Schoner W. Pulse pressure correlates with a proscillaridin A immunoreactive compound. Hypertension 27: 1073-1078, 1996.
344. Simão Padilha A, Venturini Rossoni L, Xavier FE, Vassallo DV. Ouabain at nanomolar concentration promotes synthesis and release of angiotensin II from the endothelium of the tail vascular bed of spontaneously hypertensive rats. J Cardiovasc Pharmacol 44: 372-380, 2004.
345. Smith JA, Madden T, Vijjeswarapu M, Newman RA. Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin. Biochem Pharmacol 62: 469-472, 2001.
346. 2 subunits to specialized plasma membrane microdomains. J Biol Chem 281: 12929-12940, 2006.
347. Sopucleous A, Elmatzoglou I, Souvatzoglou A. Circulating endogenous digitalis-like factor(s) (EDLF) in man is derived from the adrenals and its secretion is ACTH-dependent. J Endocrinol Invest 26: 668-674, 2003.
348. Sreenivasan Y, Raghavendra PB, Manna SK. Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells. J Clin Immunol 26: 308-322, 2006.
349. Stenkvist B. Cardenolides and cancer. Anticancer Drugs 12: 635-636, 2001.
350. Subramaniam S, Unsicker K. Extracellular signal-regulated kinase as an inducer of non-apoptotic neuronal death. Neuroscience 138: 1055-1065, 2006.
351. Sumbayev VV, Yasinska IM. Regulation of MAP kinase-dependent apoptotic pathway: implication of reactive oxygen and nitrogen species. Arch Biochem Biophys 436: 406-412, 2005.
352. +-ATPase by insulin: why and how? Mol Cell Biochem 182: 121-133, 1998.
353. 1-subunit in HEK-293 cells. Am J Physiol Cell Physiol 281: C1797-C1803, 2001.
354. Szent-Györgyi A. Chemical Physiology of Contraction in Body and Heart Muscle. New York: Academic, 1953, p. 86-91.
355. Takahashi H, Matsuzawa M, Okabayashi H, Suga K, Ikegaki I, Yoshimura M, Bichi H, Okamura H, Murakami S, Ibata Y. Evidence for digitalis-like substance in the hypothalamopituitary axis in rats: implications in the central cardiovascular regulation associated with excess intake of sodium. Jpn Circ J 51: 1199-1207, 1987.
356. Tamura M, Piston D, Tani M, Naruse M, Jandon E, Inagami T. Ouabain increases aldosterone release from bovine adrenal glomerulosa cells: role of renin-angiotensin system. Am J Physiol Endocrinol Metab 270: E27-E35, 1996.
357. Taurin S, Dulin NO, Pchejetski D, Grygorczyk R, Tremblay J, Hamet P, Orlov SN. c-Fos expression in ouabain-treated vascular smooth muscle cells from rat aorta: evidence for an intracellular-sodium mediated, calcium-independent mechanism. J Physiol 543: 835-847, 2002.
358. i ratio in cultured vascular smooth muscle cells. Circ Res 91: 915-922, 2002.
359. Terness P, Navolan D, Dufter C, Kopp B, Opelz G. The T-cell suppressive effect of bufadienolides: structural requirements for their immunoregulatory activity. Int Immunopharmacol 1: 119-134, 2001.
360. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525-533, 1997.
361. Therien AG, Blostein R. Mechanisms of sodium pump regulation. Am J Physiol Cell Physiol 279: C541-C566, 2000.
362. +-ATPase forms a functional signaling complex. Mol Biol Cell 17: 317-326, 2006.
363. i in rat cardiac myocytes. Am J Physiol Heart Circ Physiol 281: H1899-H1907, 2001.
364. Tian J, Liu J, Garlid KD, Shapiro JI, Xie Z. Involvement of mitogenactivated protein kinases and reactive oxygen species in the inotropic action of ouabain on cardiac myocytes. A potential role for mitochondrial KATP channels. Mol Cell Biochem 242: 181-187, 2003.
365. Towbin JA, Bowles NE. The failing heart. Nature 415: 227-233, 2002.
366. Trevisi L, Visentin B, Cusinato F, Pighin I, Luciani S. Antiapoptotic effect of ouabain in human umbilical vein endothelial cells. Biochem Biophys Res Commun 321: 716-721, 2004.
367. Valdes R Jr. Endogenous digoxin-immunoactive factor in human subjects. Fed Proc 44: 2800-2805, 1985.
368. Van Quaquebeke E, Simon G, Andre A, Dewelle J, Yazidi M EI, Bruyneel F, Tuti J, Nacoulma O, Guissou P, Decaestecker C, Braekman JC, Kiss R, Darrot F. Identification of a novel cardenolide (2″-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: structure-activity relationship analyses. J Med Chem 48: 849-856, 2005.
369. Veerasingham SJ, Leenen FH. Ouabain- and central sodium-induced hypertension depend on the ventral anteroventral third ventricle region. Am J Physiol Heart Circ Physiol 276: H63-H70, 1999.
370. 2+ exchange activity. Am J Physiol Cell Physiol 256: C1273-C1276, 1989.
371. +-ATPase. J Biol Chem 279: 17250-17259, 2004.
372. Wang H, Huang BS, Ganten D, Leenen FHH. Prevention of sympathetic and cardiac dysfunction after myocardial infarction in transgenic rats deficient in brain angiotensinogen. Circ Res 94: 843-849, 2004.
373. Wang H, Huang BS, Leenen FHH. Brain sodium channel and ouabainlike compounds mediate central aldosterone-induced hypertension. Am J Physiol Heart Circ Physiol 285: H2516-H2523, 2003.
374. Wang H, Leenen FHH. Brain sodium channels mediate increases in brain "ouabain" and blood pressure in Dahl S rats. Hypertension 40: 96-100, 2002.
375. Wang H, Lu Z, Yuan W. Comparative study of the effect of ouabain and digoxin on blood pressure of rats. Chin Med J (Engl) 110: 911-914, 1997.
376. + channels by FMRFamide in Dahl SS and SR rats. Am J Physiol Heart Circ Physiol 285: H2013-H2018, 2003.
377. Wang H, Yuan WQ, Lu ZR. Differential regulation of the sodium pump α-subunit isoform gene by ouabain and digoxin in tissues of rats. Hypertens Res 23: S55-S60, 2000.
378. +-ATPase a-subunit isoforms have a similar affinity for cardiac glycosides. Am J Physiol Cell Physiol 281: C1336-C1343, 2001.
379. Wang JG, Staessen JA, Messagio E, Nawrot T, Fagard R, Hamlyn JM, Bianchi G, Manunta P. Salt, endogenous ouabain and blood pressure interactions in the general population. J Hypertens 2003: 1475-1481, 2003.
380. 1 receptor densities in Dahl rats. Am J Physiol Heart Circ Physiol 285: H1949-H1955, 2003.
381. Wang L, Wible BA, Wan X, Ficker E. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J Pharmacol Exp Ther 320: 525-534, 2006.
382. Wasada T, Kuroki H, Naruse M, Arii H, Maruyama A, Katsumori K, Saito S, Watanabe Y, Naruse K, Demura H, Omori Y. Insulin resistance is associated with high plasma ouabain-like immunoreactivity concentration in NIDDM. Diabetologia 38: 792-797, 1995.
383. Wasserstrom JA, Aistrup GL. Digitalis: new actions for an old drug. Am J Physiol Heart Circ Physiol 289: H1781-H1793, 2005.
384. Watabe M, Ito K, Masuda Y, Nakajo S, Nakaya K. Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. Oncogene 16: 779-787, 1998.
385. Watabe M, Kawazoe N, Masuda Y, Nakajo S, Nakaya K. Bcl-2-protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells. Cancer Res 57: 3097-3100, 1997.
386. Watabe M, Masuda Y, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K. The cooperative interaction of two different signaling pathways in response to bufalin induces apoptosis in human leukemia U937 cells. J Biol Chem 271: 14067-14073, 1996.
387. Wattenberg EV. Palytoxin: exploiting a novel skin tumor promoter to explore signal transduction and carcinogenesis. Am J Physiol Cell Physiol 292: C24-C32, 2007.
388. Weidemann H. Na/K-ATPase, endogenous digitalis-like compounds and cancer development - a hypothesis. Front Biosci 10: 2165-2176, 2005.
389. Weidemann H, Salomon N, Avnit-Sagi T, Weidenfeld J, Rosen H, Lichtstein D. Diverse effects of stress and additional adrenocorticotropic hormone on digitalis-like compounds in normal and nude mice. J Neuroendocrinol 16: 1-6, 2004.
390. Weil E, Sasson S, Gutman Y. Mechanism of insulin-induced activation of Na,K-ATPase in isolated rat soleus muscle. Am J Physiol Cell Physiol 261: C224-C230, 1991.
391. Whitmarsh AJ, Davis RJ. Structural organization of MAP kinasesignaling molecules by scaffold proteins in yeast and mammals. Trends Biochem Sci 23: 481-485, 1998.
392. Williams SS, French JN, Gilbert M, Rangaswami AA, Walleczek J, Knox SJ. Bcl-2 overexpression results in enhanced capacitative calcium entry and resistance to SKF-96395-induced apoptosis. Cancer Res 60: 4358-4361, 2000.
393. Woroniecki R, Ferdinand JR, Morrow JS, Devarajan P. Dissociation of spectrin-ankyrin complex as a basis for loss of Na-K-ATPase polarity after ischemia. Am J Physiol Renal Physiol 284: F358-F364, 2003.
394. Xavier FE, Yogi A, Cállera GE, Tostes RC, Yolanda Alvarez Salaices M, Alonso MJ, Rossoni LV. Contribution of the endothelin and reninangiotensin systems to the vascular changes in rats chronically treated with ouabain. Br J Pharmacol 143: 794-802, 2004.
395. Xie JT. Ouabain enhances basal release of nitric oxide from carotid artery. Am J Med Sci 305: 157-163, 1993.
396. +-ATPase as a signal inducer. Eur J Biochem 269: 2434-2439, 2002.
397. +-ATPase-mediated signal transduction: from protein interaction to cellular function. Mol Interventions 3: 157-168, 2003.
398. +-ATPase to hypertrophy and its marker genes in cardiac myocytes. J Biol Chem 274: 19323-19328, 1999.
399. Xing H, Zhang SL, Weinheimer C, Kovacs A, Muslin A. 14-3-3 proteins block apoptosis and differentially regulate MAPK cascades. EMBO J 270: 349-358, 2000.
400. Yamada K, Goto A, Hui C, Omata M. Role of ouabain-like compound in the regulation of plasma aldosterone concentration in rats. Life Sci 38: 1833-1837, 1996.
401. Yamada K, Goto A, Nagoshi H, Terano Y, Omata M. Elevation of ouabain-like compound levels with hypertonic sodium chloride load in rat plasma and tissues. Hypertension 30: 94-98, 1997.
402. Yamada K, Goto A, Omata M. Adrenocorticotropin-induced hypertension in rats: role of ouabain-like compound. Am J Hypertens 10: 403-408, 1997.
403. Yamada K, Goto A, Omata M. Modulation of the levels of ouabain-like compound by central catecholamine neurons in rats. FEBS Lett 360 67-69, 1995.
404. Yamada K, Hino Ki, Omoyasu ST, Honma Y, Tsuruoka N. Enhancement by bufalin of retinoic acid-induced differentiation of acute promyelocytic leukemia cells in primary culture. Leuk Res 22: 589-595, 1998.
405. Yeh JY, Huang WJ, Kan SF, Paulus SW. Inhibitory effects of digitalis on the proliferation of androgen-dependent and -independent prostate cancer cells. J Urol 166: 1937-1942, 2001.
406. Yeh JY, Huang WJ, Kan SF, Wang PS. Effects of bufalin and cinobufagin on the proliferation of androgen-dependent and -independent prostate cancer cells. Prostate 54: 112-124, 2003.
407. Yuan CM, Manunta P, Hamlyn JM, Chen S, Bohen E, Yeun J, Haddy FJ, Pamnani MB. Long-term ouabain administration produces hypertension in rats. Hypertension 22: 178-187, 1993.
408. 3 receptor into a calcium-regulatory complex. Mol Biol Cell 16: 4034-4045, 2005.
409. +-ATPase α-subunit and regulates its trafficking. Proc Natl Acad Sci USA 97: 6556-6561, 2000.
410. Zahler R, Gilmore-Hebert M, Baldwin J, Franeo K, Benz E Jr. Expression of α-isoforms of the Na,K-ATPase in human heart. Biochim Biophys Acta 1149: 189-194, 1993.
411. 2-subunits control myogenic tone and blood pressure in mice. J Physiol 569: 243-256, 2005.
412. Zhang L, Hakaya K, Yoshidal T, Kuroiwal Y. Bufalin as a potent inducer of differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 178: 686-693, 1991.
413. Zhang L, Yoshida T, Kuroiwa Y. Stimulation of melanin synthesis of B16-F10 mouse melanoma cells by bufalin. Life Sci 51: 17-24, 1992.
414. Zhang S, Malmersjö S, Li J, Ando H, Aizman O, Uhlén P, Mikoshiba K, Aperia A. Distinct role of the N-terminal tail of the Na,K-ATPase catalytic subunit as a signal transducer. J Biol Chem 281: 21954-21962 2006.
415. Zhang Z, Devarajan P, Dorfman AL, Morrow JS. Structure of the ankyrin-binding domain of α-Na,K-ATPase. J Biol Chem 273: 18681-18684, 1998.
416. Zhao X, White R, Huang BS, Van Huysse J, Leenen FHH. High salt intake and the brain renin-angiotensin system in Dahl salt-sensitive rats. J Hypertens 19: 89-98, 2001.
417. Zhou X, Jiang G, Zhao A, Bondeva T, Hirszel P, Balla T. Inhibition of Na,K-ATPase activates PI3 kinase and inhibits apoptosis in LLC-PK1 cells. Biochem Biophys Res Commun 285: 46-51, 2001.
418. Zhu Z, Tepel M, Neusser M, Zidek W. Low concentrations of ouabain increase cytosolic free calcium concentration in rat vascular smooth muscle cells. Clin Sci (Lond) 90: 9-12, 1996.